In a report issued on July 24, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST), with a price target of $31.00. The company’s shares closed last Monday at $5.26.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 6.4% and a 49.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Aquestive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.00 and a one-year low of $1.41. Currently, Aquestive Therapeutics has an average volume of 1.02M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
